Jiang C et al. [37] determined that ADH1B may suppress the invasion, proliferation and migration of BC cells by suppressing mitogen-activated protein kinase (MAPK) signaling pathway, so it may be a potential clinical therapeutic target for BC. This evidence concerns the gene WNK2 and breast cancer.